Our Cell Therapies
We are committed to developing transformative cell therapies to improve outcomes for patients with solid tumors.
We are committed to developing transformative cell therapies to improve outcomes for patients with solid tumors.
We are committed to developing transformative cell therapies to improve outcomes for patients with solid tumors.
Our body’s immune system can recognize cancer cells as abnormal and kill them. However, this process can fail to get rid of cancer cells entirely. Immunotherapy is a treatment for some types of cancer that helps the body’s immune system find and kill cancer cells.
Autologous T-cell therapy is a highly personalized immunotherapy that involves taking cells from the patient, improving their functionality and transferring them back to the patient. By reprogramming the T cells, they can be designed with the potential to address a wide range of diseases, including cancer. Unlike other cancer therapies that might require ongoing treatments, cell therapies often offer a one-time treatment option.
90% of cancers are solid tumors. Yet, cell therapies have shown limited success in treating solid tumors. Our goal is to change this. Our T-cell reprogramming technologies are designed to address efficacy barriers to cell therapy in solid tumors.
Learn MoreLearn more about Lyell's approach and capabilities to tackling solid tumors with cell therapy.
Some cancer cells have biomarkers or antigens (types of proteins) on their cell surface. CAR T cells are modified to recognize and kill the cancer cells that have a specific biomarker.
Some cancer-fighting immune cells are able to recognize and infiltrate solid tumors to kill cancer cells. TIL therapy involves collecting tumor cells via surgery and growing large numbers of cancer-fighting T cells that are already found in the tumor.
Genetic Reprogramming, which includes our c-Jun overexpression and NR4A3 knockout technologies, aims to delay exhaustion and create more potent T cells with enhanced and long-lasting cancer-fighting ability
Epigenetic Reprogramming, which includes our Epi-R™ manufacturing protocol and Stim-R™ technology, aims to enhance qualities of stemness, persistence and function of T cells to drive potent and long-lasting cancer cell killing
The participation of patients and their families in clinical trials enables us to evaluate our investigational product candidates for safety and efficacy. We are driven to defeat cancers and are grateful for those who choose to join us on this journey.
Stage: Phase 1 trial to evaluate the safety and tolerability of LYL797 in patients with ROR1+ relapsed or refractory TNBC, NSCLC, platinum-resistant ovarian cancer or endometrial cancer
More info: Visit ClinicalTrials.gov or email clinicaltrialslyell.com
Stage: Phase 1 trial to evaluate the safety and tolerability of LYL797 in patients with ROR1+ relapsed or refractory TNBC, NSCLC, platinum-resistant ovarian cancer or endometrial cancer
More info: Visit ClinicalTrials.gov or email clinicaltrialslyell.com
Stage: Phase 1 trial to evaluate the safety and tolerability of LYL845 in patients with relapsed and/or refractory metastatic or locally advanced melanoma, NSCLC or colorectal cancer
More info: Visit ClinicalTrials.gov or email clinicaltrialslyell.com
Stage: Phase 1 trial to evaluate the safety and tolerability of LYL797 in patients with ROR1+ relapsed or refractory TNBC, NSCLC, platinum-resistant ovarian cancer or endometrial cancer
More info: Visit ClinicalTrials.gov or email clinicaltrialslyell.com
Stage: Phase 1 trial to evaluate the safety and tolerability of LYL119 in patients with ROR1+ relapsed or refractory platinum-resistant ovarian cancer or endometrial cancer, with subsequent expansion into other tumor types including NSCLC and TNBC
More info: Email clinicaltrialslyell.com
Stage: Phase 1 trial to evaluate the safety and tolerability of LYL797 in patients with ROR1+ relapsed or refractory TNBC, NSCLC, platinum-resistant ovarian cancer or endometrial cancer
More info: Visit ClinicalTrials.gov or email clinicaltrialslyell.com
Stage: Phase 1 trial to evaluate the safety and tolerability of LYL119 in patients with ROR1+ relapsed or refractory platinum-resistant ovarian cancer or endometrial cancer, with subsequent expansion into other tumor types including NSCLC and TNBC
More info: Email clinicaltrialslyell.com
Stage: Phase 1 trial to evaluate the safety and tolerability of LYL845 in patients with relapsed and/or refractory metastatic or locally advanced melanoma, NSCLC or colorectal cancer
More info: Visit ClinicalTrials.gov or email clinicaltrialslyell.com
Stage: Phase 1 trial to evaluate the safety and tolerability of LYL845 in patients with relapsed and/or refractory metastatic or locally advanced melanoma, NSCLC or colorectal cancer
More info: Visit ClinicalTrials.gov or email clinicaltrialslyell.com